Dr. Jie Xu, as the scientifc funder and advisor of BioTroy, is a senior researcher in the fields of translational oncology and oncoimmunotherapy. His research group discovered regulatory mechanisms of immune checkpoint pathways and developed promising lead compounds such as PD-LYSO and PD-PALM. In the recent years, his research focused on the identification of novel and key mechanisms in cancer immune evasion, which led to the discovery of promising first-in-class therapeutic antibodies under preclinical development.
Selected publications:
J Immunother Cancer. 2021;9(8):e002443.
Regulation of Cancer Immune Checkpoints. Springer Book. 2020 ISBN: 9811532656
Nature Chemical Biology, 2019 (1): 42~50
Nature Biomedical Engineering, 2019; 3(5):414
Editorship:
Frontiers in Immunology, Associate Editor
Frontiers in Pharmacology, Associate Editor
Frontiers in Oncology, Associate Editor
